Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 206

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 6
Chunk 206
---
1, Mr. Melnyk served as the chief executive officer of Fortovia Therapeutics, Inc., a commercial stage, pharmaceutical company
focused on oncology supportive care products. From 2011 until 2017, Mr. Melnyk was chief commercial officer at NovoCure Limited (NASDAQ:
NVCR), a cancer medical device company, where he built a global commercial platform and infrastructure to launch a new modality of anticancer
technology. Mr. Melnyk was previously senior vice president for global sales and marketing at OSI Pharmaceuticals, Inc., a U. S. pharmaceutical
company, where he led the global commercialization efforts for Tarceva, a chemotherapy drug, from 2003 to 2011. Prior to that, Mr. Melnyk
was the executive director of oncology at Pharmacia Oncology from 2001 until 2003, until its acquisition by Pfizer, Inc. Mr. Melnyk also
served in various capacities at Bristol-Myers Squibb Company from 1991 until 2001. Mr. Melnyk holds a B. Sc in Animal Science and M. Sc
in reproductive endocrinology from McGill University.

Directors

Michael Avruchhas
served as a member of our board of directors since 2016. Mr. Avruch has served as chief executive officer, chief financial officer, and
as a member of the board of directors of Sabor LTD (The Sabor Group Europe) since 1998 and Sabor Venture Capital Investments (VCI) LTD
since 2017. Mr. Avruch has also served as chief executive officer and chief financial officer of Sabor Group USA since 2015. Mr. Avruch
has experience in the real estate, services, and trade sectors in multiple countries in Europe and the USA. Mr. Avruch holds a B. A. in
Management Accounting and Information Systems from the Jerusalem College of Technology and an MBA from Bar Ilan University. We believe
Mr. Avruch’s financial and cross-border experience qualify him to serve on our board of directors.

Ruth Alonhas
served on our Board since March 2022. Ms. Alon is currently the founder and CEO of Medstrada. From 1997 and until September 24,
2016, Ms. Alon served as a general partner in Pitango Venture Capital. Prior to her tenure at Pitango, Ms. Alon held senior